Related Experiment Video
Updated: Jun 19, 2026
08:02
Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
Published on: April 25, 2016
Deflazacort versus other glucocorticoids: a comparison
Surajit Nayak1, Basanti Acharjya
1Department of Skin and VD, MKCG Medical College and Hospital, Berhampur, Orissa 760004, India. surajitnyk@yahoo.co.in
Indian Journal of Dermatology
|November 3, 2009
Summary
This review discusses deflazacort, a new glucocorticoid steroid derivative, highlighting its basic properties, advantages, and disadvantages in dermatological therapy. It addresses the need for more Indian-specific research on this prednisolone derivative.
Area of Science:
- Dermatology
- Pharmacology
- Endocrinology
Background:
- Corticosteroids are mainstays in dermatological treatment for various conditions.
- Long-term use of corticosteroids is associated with significant side effects.
- Deflazacort, a novel glucocorticoid and prednisolone derivative, has recently entered the Indian market.
Purpose of the Study:
- To review the fundamental aspects of deflazacort.
- To evaluate the claimed benefits and potential drawbacks of deflazacort in dermatological therapy.
- To address the limited Indian-specific research on deflazacort.
Main Methods:
- Literature review of existing studies on deflazacort.
- Comparative analysis of deflazacort with other corticosteroids.
- Examination of pharmacological properties and clinical data.
Main Results:
- Deflazacort is a glucocorticoid with potential for reduced side effects compared to older steroids.
- Limited clinical data, particularly from Indian populations, exists for deflazacort.
- Further research is needed to fully establish its efficacy and safety profile.
Conclusions:
- Deflazacort represents a new option in dermatological steroid therapy.
- Its long-term safety and efficacy require further investigation, especially in the Indian context.
- Understanding its advantages and disadvantages is crucial for clinical application.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...